Alembic Pharmaceuticals shares surge over 6.5% amid spike in trading volumes

Shares of the Vadodara-based drug maker Alembic Pharmaceuticals rose as much as 6.65% to hit an intraday high of ₹958.50 on the BSE. On the National Stock Exchange (NSE), Alembic Pharmaceuticals shares advanced as much as 6.5% to hit an intraday high of ₹958 amid higher than usual trading volumes.

Alembic Pharmaceuticals posted its best single day performance in nearly five months. Last time the stock moved over 6.65% was on June 30, when the stock surged 7.27%.

Trading volumes in Alembic Pharma spiked by nearly 36 times to 39.92 lakh shares compared with an average trading volume of 1.11 lakh shares on the NSE. On the BSE as many as 1.75 lakh shares changed hands compared with an average of 4,618 shares traded daily in the past two weeks.

Last week, the company informed exchanges that it got final approval from the US Food and Drug Administration's (USFDA) for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg.

Alembic Pharma received final approval for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem Tablets, 30 mg, 60 mg, 90 mg, and 120 mg, of Bausch Health US, LLC.

According to IQVIA data for the 12 months ending June 2025 (MAT June 2025), the annual sales for Diltiazem Hydrochloride Tablets in the United States were estimated at $13.9 million.

Diltiazem Hydrochloride extended-release capsules market size was estimated at approximately $105.3 million for the 12 months ending June 2024, Business Standard reported citing IQVIA data mentioned.

The drug is indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Alembic has a cumulative total of 230 ANDA approvals (210 final approvals and 20 tentative approvals) from USFDA, the company said in a press release.

Alembic Pharmaceuticals shares erased most of the intraday gains to end 0.17% higher at ₹901.